AVROBIO, Inc (AVRO) Prices 4.35M Share Common Offering at $23/Sh

After-Hours Stock Movers 02/12: (RDFN) (FBIO) (AMAT) Higher; (BE) (NTAP) (CSCO) Lower (more...)

Today's After-Hours Movers

Bloom Energy (NYSE: BE) 19% LOWER; today announced that the Company expects to present its fourth quarter and full year results on or before March 16, 2020 and to file its Annual Report on Form 10-K for the year ended December 31, 2019 in compliance with the required filing deadline. The Company also announced it will restate certain prior period financial statements due to an accounting error related to its Managed Services Agreements (MSAs). MSAs are one of the Companys three customer financing options to acquire Bloom Energy servers

Akerna Corp. (Nasdaq:... More

AVROBIO, Inc (AVRO) Announces Proposed $100M Public Offering of Common Stock

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering.

The company expects to grant the underwriters a 30-day... More

Avrobio Inc. (AVRO) PT Raised to $40 at Morgan Stanley

Morgan Stanley analyst David Lebowitz raised the price target on Avrobio Inc. (NASDAQ: AVRO) to $40.00 (from $37.00) while maintaining a Overweight rating.... More

Avrobio Inc. (AVRO) PT Raised to $36 at Wedbush

Wedbush analyst David Nierengarten raised the price target on Avrobio Inc. (NASDAQ: AVRO) to $36.00 (from $32.00) while maintaining a Outperform rating after the company updated their gene therapy program in Fabry disease (AVR-RD-01) and gave a first look at their program in cystinosis (AVR-RD-04).

Avrobio Inc. (AVRO) PT Raised to $35 at Mizuho Securities

Mizuho Securities analyst Difei Yang raised the price target on Avrobio Inc. (NASDAQ: AVRO) to $35.00 (from $28.00) while maintaining a Buy rating.... More